IMO and the Multiple Myeloma Research Foundation (MMRF), a leading cancer nonprofit organization dedicated to accelerating a cure for multiple myeloma, have partnered in order to jointly work to improve the utility of the clinical data from MMRF’s CureCloud and CoMMpass clinical trials.
The added capabilities provided by IMO’s data normalization services will enhance the utility of the MMRF’s data for use cases such as patient identification for clinical trials, cohort selection for health outcomes research, and the enhanced ability to provide analytic precision to the MMRF’s real-world data sources. Through the CureCloud and CoMMpass research programs, the MMRF has generated some of the richest oncology data sets to drive new precision treatments and a cure for each and every myeloma patient.
“We are looking forward to partnering with IMO to streamline data analysis,” said Steven Labkoff, MD, MMRF’s Chief Data Officer. “As data leaves the electronic health records (EHRs), crucial metadata elements are often lost when EHRs create human-readable records. By utilizing IMO technology, we will be able to re-introduce this data, which in turn will help us to generate insights and, more importantly, help our researchers to more easily utilize our data in an effort to find cures.”
Recognizing an opportunity to gain more impactful insights from that data, MMRF partnered with IMO to leverage its IMO Precision Normalize technology, which standardizes inconsistent diagnosis, procedure, medication, and lab data from diverse systems into a common, clinical terminology.
Used by over 500,000 physicians during point of care documentation, IMO clinical terminology forms the foundation of IMO Precision Normalize, helping IT leaders and data stewards address the challenges that come with managing and leveraging data derived from multiple health information systems and sources.